Internal Medicine, Cardiovascular Disease · Bronx, NY
NPI
1245528975
Since 2011
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1963 Williamsbridge Rd
Bronx, NY, 10461
Phone (646) 530-8447
Groups this clinician bills Medicare through
Medicare paid, 2024
$220K
3,010 services
Medicare patients, 2024
418
Average age 73
Drug cost, 2024
$2.1M
9,747 prescriptions
Company payments, 2025
$460
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anna Kezerashvili was code 93000 (electrocardiogram), 427 times for 204 patients. In total Anna Kezerashvili billed 3,010 services in 49 codes, and Medicare paid $220K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 93000 Electrocardiogram | Office | 427 | 204 | $11.45 | $4,890 |
| 99213 Office E&M - Established | Office | 317 | 142 | $74.36 | $24K |
| 93306 Echocardiography (TTE/TEE) | Office | 185 | 172 | $172.61 | $32K |
| 99458 E&M - Miscellaneous | Office | 155 | 16 | $35.44 | $5,493 |
| 93880 Duplex Scan - Extracranial Arteries | Office | 152 | 152 | $144.28 | $22K |
| 99457 E&M - Miscellaneous | Office | 134 | 17 | $44.51 | $5,964 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 121 | 18 | $55.61 | $6,729 |
| 99454 E&M - Miscellaneous | Office | 117 | 13 | $44.55 | $5,212 |
| 93970 Duplex Scan - Extremity Veins | Office | 96 | 88 | $91.62 | $8,796 |
| 93016 Electrocardiogram | Office | 95 | 95 | $17.78 | $1,689 |
| 93018 Electrocardiogram | Office | 95 | 95 | $11.97 | $1,137 |
| 78452 Myocardial Perfusion Scan | Office | 94 | 94 | $62.40 | $5,865 |
| 95923 Electrical Nerve Conductivity | Office | 77 | 74 | $106.11 | $8,171 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 77 | 15 | $42.72 | $3,289 |
| 93923 Duplex Scan - Extremity Arteries | Office | 70 | 70 | $59.19 | $4,143 |
By year: 2022 $215K for 2,701 services; 2023 $243K for 3,149 services; 2024 $220K for 3,010 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 46 | 39 | $4.90 | $225 |
Medicare prescription drug claims, 2024
In 2024, the drug Anna Kezerashvili prescribed most often to Medicare patients was Atorvastatin Calcium, with 967 prescriptions and refills. In total Anna Kezerashvili wrote 9,747 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 967 | 2,390 | 340 | $9,048 |
| Amlodipine Besylate Generic | 658 | 1,626 | 230 | $3,577 |
| Losartan Potassium Generic | 622 | 1,437 | 205 | $4,768 |
| Rosuvastatin Calcium Generic | 529 | 1,292 | 200 | $6,667 |
| Metoprolol Succinate Generic | 516 | 1,210 | 156 | $6,496 |
| Entresto Sacubitril/Valsartan | 429 | 697 | 94 | $447K |
| Vascepa Icosapent Ethyl | 333 | 516 | 71 | $159K |
| Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide | 305 | 738 | 103 | $6,700 |
| Carvedilol Generic | 296 | 553 | 82 | $1,548 |
| Hydrochlorothiazide Generic | 293 | 733 | 109 | $928 |
| Ranolazine Er Ranolazine | 234 | 434 | 51 | $20K |
| Ezetimibe Generic | 225 | 582 | 78 | $4,388 |
| Lisinopril Generic | 202 | 534 | 68 | $1,060 |
| Labetalol Hcl Generic | 197 | 388 | 50 | $3,869 |
| Simvastatin Generic | 181 | 456 | 56 | $1,052 |
Brand drugs: 2,067 claims; generic drugs: 7,680 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anna Kezerashvili $460 ($460 in general payments such as food, travel and fees) from 4 companies. The largest payer was Heartflow, Inc. with $278.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.